Datasets:
ClarusC64
/
clarus-population-framework-transition-integrity-v0.1

Dataset card Data Studio Files
xet
Community
sample_id
string
source_framework
string
target_framework
string
concept
string
source_definition
string
target_definition
string
claim
string
option_a
string
option_b
string
task
string
correct_option
string
required_note
string
required_keywords
string
axis
string
difficulty
int64
CPFT-0001
Registry
Publication
Inclusion criteria
Age 18–75
Age 18–65
Claim same enrolled population
Invalid correspondence, age range narrowed
Valid correspondence, minor edit
Judge correspondence and write note
A
State 18–75 vs 18–65 and flag narrowed eligibility
18–75|18–65|age|narrowed|eligibility
inclusion_criteria
2
CPFT-0002
Registry
SAP
Analysis set
ITT includes all randomized
mITT excludes no-dose patients
Treat ITT and mITT as identical
Invalid correspondence, analysis set changed
Valid correspondence, mITT fully mapped
Judge correspondence and write note
A
State ITT vs mITT and require explicit exclusion mapping
ITT|mITT|exclude|no dose|mapping
analysis_set
3
CPFT-0003
Protocol
Publication
Exclusion criteria
No prior anti-PD-1
Prior anti-PD-1 allowed in analysis
Assume criteria unchanged
Invalid correspondence, exposure rule changed
Valid correspondence, same rule
Judge correspondence and write note
A
State prior anti-PD-1 change and flag population drift
prior anti-PD-1|allowed|exposure|drift|criteria
exclusion_criteria
3
CPFT-0004
Protocol
SAP
Stratification factor
Stratify by EGFR status
Stratify by EGFR and smoking
Assume same strata
Partial correspondence, strata expanded
Valid correspondence, unchanged
Judge correspondence and write note
A
State added smoking stratification and note comparability impact
EGFR|smoking|stratify|expanded|comparability
stratification
2
CPFT-0005
Registry
Publication
High-risk subgroup
High risk = prior MI
High risk = prior MI or diabetes
Treat subgroup as same
Partial correspondence, definition broadened
Valid correspondence, same subgroup
Judge correspondence and write note
A
State MI-only vs MI-or-diabetes and flag broadened subgroup
MI|diabetes|high risk|broadened|definition
subgroup_definition
2
CPFT-0006
Protocol
Publication
Missing data handling
All randomized included
Exclude patients missing baseline scan
Assume cohort unchanged
Invalid correspondence, exclusions added
Valid correspondence, same cohort
Judge correspondence and write note
A
State baseline scan exclusion and flag post-randomization selection
missing baseline|exclude|post-randomization|selection|cohort
missingness_selection
3
CPFT-0007
Registry
Publication
Enrollment geography
Global sites
EU sites only in analysis
Treat as same population
Invalid correspondence, geography restricted
Valid correspondence, same sites
Judge correspondence and write note
A
State global vs EU-only and flag restricted external validity
global|EU only|geography|restricted|external validity
population_scope
3
CPFT-0008
Protocol
SAP
Per-protocol set
Not defined
Per-protocol excludes major deviations
Report PP as primary without mapping
Invalid correspondence, primary set changed
Valid correspondence, PP secondary only
Judge correspondence and write note
A
State per-protocol introduced and require mapping from ITT
per-protocol|deviations|primary|mapping|ITT
analysis_set_shift
3
CPFT-0009
Registry
Publication
Run-in period
No run-in
2-week placebo run-in excludes non-adherent
Treat as same enrolled group
Invalid correspondence, selection introduced
Valid correspondence, run-in documented and mapped
Judge correspondence and write note
A
State run-in selection and flag adherence-based exclusion
run-in|placebo|non-adherent|selection|exclude
selection_mechanism
3
CPFT-0010
Protocol
Publication
Substudy cohort
All participants eligible
Only biomarker-positive included
Treat substudy results as trial-wide
Invalid correspondence, cohort restricted
Valid correspondence, restricted cohort stated
Judge correspondence and write note
A
State biomarker-positive restriction and block generalization
biomarker-positive|restricted|cohort|generalize|trial-wide
generalization
3